MedTrace Logo

Outpatient Management of Preterm Prelabor Rupture of Membranes

NCT05755841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2023-03-22

No results posted yet for this study

Summary

Home-care management is possible if patients are clinically stable forty-eight hours after Preterm Prelabour Rupture of the membrane with no clinical or biological signs suggestive of intrauterine infection. Several retrospective studies have highlighted the safety of such outpatient management for women with nonthreatening Preterm Prelabour Rupture of the membrane. This prospective cohort study will compare inpatient versus outpatient management of preterm Prelabour rupture of membrane regarding latency, intra-amniotic infection, birth weight, and neonatal complications at 28 to 34 weeks of gestation after 48 hours of admission to Ain-Shams University Maternity Hospital.

Conditions

  • Management of Preterm Prelabor Rupture of Membranes

Interventions

OTHER

Outpatient management of preterm prelabor rupture of membranes

Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management: * Twice weekly fetal cardiotocography. * Complete blood count once a week. * A weekly clinical and ultrasound examination.

OTHER

Inpatient management of preterm prelabor rupture of membranes

In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-01
Completion
2023-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05755841 on ClinicalTrials.gov